As a GIP/GLP-1 receptor agonist, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying
and (3) direct impairment of -cell insulin secretion via glucocorticoid receptor (GR)-mediated transcriptional suppression ( mTOR Inhibitors: Sirolimus and everolimus impair -cell mass via inhibition of the mTORC1 pathway, leading to reduced -cell proliferation and induction of apoptosis
During a weight loss journey, you might also get fewer nutrients and not enough protein, calcium, or vitamin D all of which are needed for healthy bones
Thyroid-related adverse events occurred in less than 1% of tirzepatide participants, supporting a strong safety signal
If [a weight-loss medication] does quiet the voicesif thats a part of itnow, Im interested in it because that would be really great, she said
Diabetes Therapy, 11(3), 755-769